RVRoberto Villaseñor

Roberto Villaseñor

*This is an algorithmically generated author record based on publicly available information.

Roberto Villaseñor has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrin-dependent trafficking of CD98hc reduces endocytic noise to maintain metabolic homeostasis

    by F Sila Rizalar, Hans Peter Grimm, Angelique Augustin, Jose L Garcia-Cordero, Roberto Villaseñor

    A stable supply of amino acids is essential for cellular homeostasis. CD98hc is an indispensable component of the LAT1 amino acid transporter. Here, we found an unexpected role for β1-integrin in amino acid homeostasis via the regulation of CD98hc trafficking. We identified Fast Endophilin-Mediated Endocytosis (FEME) as the primary internalization route for CD98hc in both osteosarcoma and brain endothelial cells. Endocytosis was followed by β1-integrin-dependent recycling, which diverted CD98hc from early endosomes. By combining mathematical modelling with high-content imaging, we demonstrate that this trafficking pathway exhibited emergent properties that filtered high-frequency endocytic events to stabilize CD98hc at the plasma membrane. Mutating CD98hc to disrupt its interaction with β1-integrin led to redistribution of the transporter into early endosomes, reduced intracellular amino acid levels and impaired growth under metabolic stress. We propose that regulation of transporter trafficking dynamics is a general mechanism to buffer endocytic noise and maintain metabolic homeostasis.

  • Open Access

    Integrin-dependent trafficking of CD98hc reduces endocytic noise to maintain metabolic homeostasis

    by F. Sila Rizalar, Hans Peter Grimm, Angelique Augustin, José L García-Cordero, Roberto Villaseñor

    A stable supply of amino acids is essential for cellular homeostasis. CD98hc is an indispensable component of the LAT1 amino acid transporter. Here, we found an unexpected role for β1-integrin in amino acid homeostasis via the regulation of CD98hc trafficking. We identified Fast Endophilin-Mediated Endocytosis (FEME) as the primary internalization route for CD98hc in both osteosarcoma and brain endothelial cells. Endocytosis was followed by β1-integrin-dependent recycling, which diverted CD98hc from early endosomes. By combining mathematical modelling with high-content imaging, we demonstrate that this trafficking pathway exhibited emergent properties that filtered high-frequency endocytic events to stabilize CD98hc at the plasma membrane. Mutating CD98hc to disrupt its interaction with β1-integrin led to redistribution of the transporter into early endosomes, reduced intracellular amino acid levels and impaired growth under metabolic stress. We propose that regulation of transporter trafficking dynamics is a general mechanism to buffer endocytic noise and maintain metabolic homeostasis.

  • Open Access

    Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle TM variants

    by Tatjana Sela, Tamara Wirth, Annika Sommer, Vincent Larraillet, Joachim Butzer, Sabine Lohmann, Pia Wittmann, Christian Klein, Hendrik Knoetgen, Roberto Villasenor, et al.

    Antisense oligonucleotides (ASOs) represent a promising therapeutic modality for central nervous system (CNS) disorders, offering highly specific modulation of gene expression. However, their clinical utility is severely limited by their inability to cross the blood-brain barrier (BBB), necessitating effective shuttling strategies. While transferrin receptor (TfR1)-mediated shuttling has shown therapeutic promise, the fundamental mechanisms governing the delivery of antibody-ASO conjugates across the BBB remain poorly understood. This study directly addresses this critical knowledge gap by establishing a mechanistic understanding of how the ASO cargo impacts major cellular interactions during the BrainshuttleTM-mediated transport across the BBB. Using a panel of advanced in vitro assays developed specifically for this purpose, including quantitative transcytosis, detailed imaging-based intracellular trafficking, and binding assays with brain endothelial cells (BECs), the shuttling process was systematically investigated. We demonstrate that ASO conjugation profoundly alters the cellular fate of the BrainshuttleTM. Specifically, conjugation increased the binding to BECs of low-affinity TfR1 shuttles via avidity effects while paradoxically reducing the binding strength of high-affinity shuttles. Functional assays confirmed the biological activity of the delivered ASOs; however, transcytosis of high-to-moderate affinity binders across the BBB model was significantly delayed upon ASO conjugation. Building on these mechanistic insights, we engineered TfR1 BrainshuttlesTM with optimized affinity and explored the shuttling potential of an alternative BBB receptor, CD98hc. These efforts culminated in the development of a novel bispecific BrainshuttleTM targeting both CD98hc and TfR1. This dual-targeting strategy exploits distinct and potentially non-competing trafficking pathways to overcome ASO-induced delays and significantly enhance in vitro transcytosis efficiency. The in vitro findings in this study underscore the necessity of mechanism-driven design to overcome ASO-induced limitations in delivery across the BBB. The bispecific CD98/TfR1 approach presented here provides a promising new strategy for maximizing delivery efficiency and enabling more effective therapeutic outcomes for CNS diseases.


  • Open Access

    ApoE4 disrupts intracellular trafficking and iron homeostasis in a reproducible iPSC-based model of human brain endothelial cells

    by Luisa Bell, Shane Clerkin, Sila Rizalar, Antoine Rizkallah, Nadine Stokar-Regenscheit, Xandor M. Spijkers, Nienke R. Wevers, Claire Simonneau, Angélique Augustin, Barbara Höllbacher, et al.


  • Open Access

    A CRISPR/Cas9 screen reveals proteins at the endosome-Golgi interface that modulate cellular ASO activity

    by Liza Malong, Jessica Roskosch, Carolina Hager, Jean-Philippe Fortin, Roland Schmucki, Marinella G. Callow, Christian Weile, Valentina Romeo, Christoph Patsch, Scott Martin, et al.

    Anti-sense oligonucleotides (ASOs) are modified synthetic single-stranded molecules with enhanced stability, activity, and bioavailability. They associate with RNA through sequence complementarity and can reduce or alter mRNA expression upon binding of splice site positions. To target RNA in the nucleus or cytoplasm, ASOs must cross membranes, a poorly understood process. We have performed an unbiased CRISPR/Cas9 knockout screen with a genetic splice reporter to identify genes that can increase or decrease ASOs activity, resulting in the most comprehensive catalog of ASOs-activity modifier genes. Distinct targets were uncovered, including AP1M1 and TBC1D23, linking ASOs activity to transport of cargo between the Golgi and endosomes. AP1M1 absence strongly increased ASO activity by delaying endosome-to-lysosome transport in vitro and in vivo . Prolonged ASOs residence time in the endosomal system may increase the likelihood of ASOs escape from this organelle before they reach lysosomes. This insight into AP1M1 role in ASOs trafficking suggests a way for enhancing the therapeutic efficacy of ASOs by manipulating the endolysosomal pathways.

  • Open Access

    ApoE4 disrupts intracellular trafficking and iron homeostasis in an improved iPSC-based model of human brain endothelial cells

    by Luisa Bell, Nadine Stokar-Regenscheit, Claire Simonneau, Angélique Augustin, Barbara Höllbacher, Lia D’abate, Joanna Ficek-Pascual, Kim Schneider, Desiree Von Tell, Chiara Zanini, et al.

    Summary: Transferrin receptor in brain endothelial cells can deliver therapeutic antibodies to the brain via transcytosis across the blood-brain barrier. Whether receptor transport remains intact in Alzheimer’s disease is still a major open question. Here, we investigated whether apolipoprotein E4 (ApoE4), the major genetic risk factor for Alzheimer’s disease, altered intracellular transport in human brain endothelial cells. To achieve this, we first developed an optimized protocol for induced pluripotent stem cells based on a defined c hemical cocktail and e xtracellular-matrix support to differentiate b rain e ndothelial c ells (iCE-BECs). Multi-omic profiling and functional transport assays showed that iCE-BECs have a brain endothelial gene signature and recapitulate receptor-mediated transcytosis of a clinically validated Brainshuttle TM antibody against transferrin receptor. Engineered iCE-BECs homozygous for ApoE4 had altered spatiotemporal organization of early endosomes, increased transferrin receptor expression and reduced cytoplasmic iron. Our data revealed that ApoE4 can impact intracellular transport and iron homeostasis at the BBB in a cell-autonomous manner. This finding could be relevant for the brain delivery of therapeutic antibodies for Alzheimer’s disease.


  • Open Access

    Microphysiological Neurovascular Barriers to Model the Inner Retinal Microvasculature

    by Thomas L. Maurissen, Georgios Pavlou, Colette Bichsel, Roberto Villaseñor, Roger D. Kamm, Héloïse Ragelle

    Blood-neural barriers regulate nutrient supply to neuronal tissues and prevent neurotoxicity. In particular, the inner blood-retinal barrier (iBRB) and blood–brain barrier (BBB) share common origins in development, and similar morphology and function in adult tissue, while barrier breakdown and leakage of neurotoxic molecules can be accompanied by neurodegeneration. Therefore, pre-clinical research requires human in vitro models that elucidate pathophysiological mechanisms and support drug discovery, to add to animal in vivo modeling that poorly predict patient responses. Advanced cellular models such as microphysiological systems (MPS) recapitulate tissue organization and function in many organ-specific contexts, providing physiological relevance, potential for customization to different population groups, and scalability for drug screening purposes. While human-based MPS have been developed for tissues such as lung, gut, brain and tumors, few comprehensive models exist for ocular tissues and iBRB modeling. Recent BBB in vitro models using human cells of the neurovascular unit (NVU) showed physiological morphology and permeability values, and reproduced brain neurological disorder phenotypes that could be applicable to modeling the iBRB. Here, we describe similarities between iBRB and BBB properties, compare existing neurovascular barrier models, propose leverage of MPS-based strategies to develop new iBRB models, and explore potentials to personalize cellular inputs and improve pre-clinical testing.


  • High Throughput Blood-brain Barrier Organoid Generation and Assessment of Receptor-Mediated Antibody Transcytosis

    by Elena Kassianidou, Claire Simonneau, Alina Gavrilov, Roberto Villaseñor

    Targeting receptor-mediated transcytosis (RMT) is a successful strategy for drug delivery of biologic agents across the blood-brain barrier (BBB). The recent development of human BBB organoid models is a major advancement to help characterize the mechanisms of RMT and thus accelerate the design of brain delivery technologies. BBB organoids exhibit self-organization, which resembles the architecture of the neurovascular unit, and low paracellular permeability, due to the formation of tight junctions between endothelial cells. However, current methods of organoid generation have low throughput, exhibit substantial heterogeneity across experiments, and require extensive manual handling. These limitations prevent the use of BBB organoids as a screening tool for discovery and optimization of therapeutic molecules. In this protocol, we use hydrogel-based arrays to generate human BBB organoids, with a 35-fold increase in organoid yield as compared to previous protocols using 96-well plates. We incubate BBB organoid arrays with monoclonal antibody-based constructs and use a custom semi-automated imaging assay to assess RMT within the organoid core. The experimental and analytical tools described in this protocol provide a scalable platform that can be incorporated in the early stages of drug discovery to accelerate the development and optimization of brain delivery technologies to cross the BBB.


  • Open Access

    Investigating receptor-mediated antibody transcytosis using blood–brain barrier organoid arrays

    by Claire Simonneau, Martina Duschmalé, Alina Gavrilov, Nathalie Brandenberg, Sylke Hoehnel, Camilla Ceroni, Evodie Lassalle, Elena Kassianidou, Hendrik Knoetgen, Jens Niewoehner, et al.

    Background: The pathways that control protein transport across the blood–brain barrier (BBB) remain poorly characterized. Despite great advances in recapitulating the human BBB in vitro, current models are not suitable for systematic analysis of the molecular mechanisms of antibody transport. The gaps in our mechanistic understanding of antibody transcytosis hinder new therapeutic delivery strategy development. Methods: We applied a novel bioengineering approach to generate human BBB organoids by the self-assembly of astrocytes, pericytes and brain endothelial cells with unprecedented throughput and reproducibility using micro patterned hydrogels. We designed a semi-automated and scalable imaging assay to measure receptor-mediated transcytosis of antibodies. Finally, we developed a workflow to use CRISPR/Cas9 gene editing in BBB organoid arrays to knock out regulators of endocytosis specifically in brain endothelial cells in order to dissect the molecular mechanisms of receptor-mediated transcytosis. Results: BBB organoid arrays allowed the simultaneous growth of more than 3000 homogenous organoids per individual experiment in a highly reproducible manner. BBB organoid arrays showed low permeability to macromolecules and prevented transport of human non-targeting antibodies. In contrast, a monovalent antibody targeting the human transferrin receptor underwent dose- and time-dependent transcytosis in organoids. Using CRISPR/Cas9 gene editing in BBB organoid arrays, we showed that clathrin, but not caveolin, is required for transferrin receptor-dependent transcytosis. Conclusions: Human BBB organoid arrays are a robust high-throughput platform that can be used to discover new mechanisms of receptor-mediated antibody transcytosis. The implementation of this platform during early stages of drug discovery can accelerate the development of new brain delivery technologies.


  • Open Access

    Investigating receptor-mediated antibody transcytosis using Blood-Brain Barrier organoid arrays

    by Claire Simonneau, Martina Duschmalé, Alina Gavrilov, Nathalie Brandenberg, Sylke Hoehnel, Camilla Ceroni, Evodie Lassalle, Hendrik Knoetgen, Jens Niewoehner, Roberto Villaseñor

    Background: The pathways that control protein transport across the Blood-Brain Barrier (BBB) remain poorly characterized. Despite great advances in recapitulating the human BBB in vitro , current models are not suitable for systematic analysis of the molecular mechanisms of antibody transport. The gaps in our mechanistic understanding of antibody transcytosis hinder new therapeutic delivery strategy development. Methods: We applied a novel bioengineering approach to generate human BBB organoids by the self-assembly of astrocytes, pericytes and brain endothelial cells with unprecedented throughput and reproducibility using micro patterned hydrogels. We designed a semi-automated and scalable imaging assay to measure receptor-mediated transcytosis of antibodies. Finally, we developed a workflow to use CRISPR/Cas9 gene editing in BBB organoid arrays to knock out regulators of endocytosis specifically in brain endothelial cells in order to dissect the molecular mechanisms of receptor-mediated transcytosis. Results: BBB organoid arrays allowed the simultaneous growth of more than 5000 homogenous organoids per individual experiment in a highly reproducible manner. BBB organoid arrays showed low permeability to macromolecules and prevented transport of human non-targeting antibodies. In contrast, a monovalent antibody targeting the human transferrin receptor underwent dose- and time-dependent transcytosis in organoids. Using CRISPR/Cas9 gene editing in BBB organoid arrays, we showed that clathrin, but not caveolin, is required for transferrin receptor-dependent transcytosis. Conclusions: Human BBB organoid arrays are a robust high-throughput platform that can be used to discover new mechanisms of receptor-mediated antibody transcytosis. The implementation of this platform during early stages of drug discovery can accelerate the development of new brain delivery technologies.